Project Summaries

  • Generic version of analgesic. Active and excipients have been sourced and formulation developed. Currently collecting data for filing. Target 4Q2022 for ANDA.
  • 505b2 formulation of opioid. Active and excipients have been sourced. Formulations development starting 1Q2018.
  • Pro-drug Project A. IBS indication, large market product. Patent filed 4Q2017.
  • Pro-drug Project B. Pro-drugs of four related active ingredients. Total combined current market over one billion.  R&D completion 2Q2018 with concomitant patent filing.